Printout from Pearl Cohen Zedek Latzer

Dov Greenbaum, Ph.D.

Dov Greenbaum, Ph.D.

Patent Attorney , Haifa

   Contact information

  • +972-4-830-1609

Admitted

  • California State Bar
  • U.S. Patent & Trademark Office

Education

Laboratory Associate, Yale University,   Department of Molecular Biophysics and Biochemistry, 2009-Present
Non-Resident Fellow, Stanford University, Center for Law and the Biosciences, 2007- Present
JD, Boalt Hall School of Law, University of California, Berkeley 2007
PhD, Yale University, 2004 (Genetics, Bioinformatics)
MPhil, Yale University, 2000 (Genetics)
Post-Doctoral Fellow, Eidgenössische Technische Hochschule Zürich (ETH Zurich) 2005-2008
BA, Yeshiva University, 1998 (Biology and Economics)

 

About Dov Greenbaum, Ph.D.

Dov Greenbaum is licensed to practice before the USPTO and in the State of California.  He has extensive experience in  patent litigation, prosecution, and strategic counseling, including: drafting briefs, reexaminations and patent applications,  preparing freedom to operate, patentability, and invalidity opinions, and conducting due diligence for mergers, acquisitions and academic institutions.

Prior to joining PCZL, Dov was a Patent Attorney specializing in medical device patent prosecution at the Israeli firm, Sanford T. Colb and Co. and an Intellectual Property Litigation Associate in the Life Sciences & Medical Products Group of the Silicon Valley office of McDermott Will & Emery LLP.  Dov has also consulted for biotechnology startups, and was a litigation department intern at Affymetrix, Inc.


 

Languages

English & Hebrew

Professional Membership

Editor, Recent Patents on DNA and Gene Sequences
Editorial Committee Journal and Health Law and Bioethics (Israel)
Member IEEE,  Institute of Electrical and Electronics Engineers (R8 region)
American Bar Association
ABA section of Science and Technology Law
 

Publications

1. Dov Greenbaum, An analysis of  Federal Circuit Discrimination: The evolution of the Written Description Requirement vis-à-vis DNA and biotechnological inventions--concerns for Synthetic Biology RECENT PATENTS ON DNA AND GENE SEQUENCES (2011).
2. Dov Greenbaum, Andrea Sboner, Xinmeng Jasmine Mu, Mark Gerstein, Genomics & Privacy: Implications of the New Reality of Closed Data for the Field,  PLOS COMPUTATIONAL BIOLOGY,  (In Press).
3. Dov Greenbaum, Patentable Subject Matter: Morally Neutral and Context Free: Ass'n for Molecular Pathology v. United States PTO, 2010 U.S. Dist. LEXIS 35418 (S.D.N.Y. Apr. 2, 2010). RECENT PATENTS ON DNA AND GENE SEQUENCES  (2011).
4. Dov Greenbaum, New Rules, Different Risk: The Changing Freedom to Operate Analysis for
Biotechnology. 11 N.C.J.L. & Tech. 139 (2010).
5. Dov Greenbaum & Christopher Scott, Hochschullehrerprivileg: A Modern Incarnation of the Professor’s Privilege to Promote University to Industry Technology Transfer, 15 SCIENCE, TECH. & SOCIETY (2010).
6. Dov Greenbaum, In Re Seagate:  Did it Really Fix the Waiver Issue? A Short Review and Analysis of Waiver Resulting from the Use Of a Counsel’s Opinion Letter as a Defense to Willful Infringement,  in PATENT LAW REVIEW  (Karen Tripp Ed.) (2009).
7. Dov Greenbaum, Academia to Industry Technology Transfer: An Alternative to the Bayh-Dole System for Both Developed and Developing Nations,  19 FORDHAM INTELLECTUAL PROPERTY, MEDIA & ENTERTAINMENT LAW JOURNAL 313 (2009).
8. Dov Greenbaum, Determining Optimal Levels of Intellectual Property Protection in Developing Nations, 97 CURRENT SCIENCE 1604 (2009).
9. Dov Greenbaum & Mark Gerstein,  Science and the Law: Grappling with the Gulf,  323 SCIENCE 210 (2009).
10. Dov Greenbaum, Pharmacogenomic Drug Development: How the FDA Can Overcome Early Missteps In Regulating Personalized Medicine,  40 RUTGERS LAW REVIEW 97 (2008).
11. Jack Lerner, Hillary Freudenthal, Dov Greenbaum, An Unspecified Country’s Patent and Designs Act: A Report Prepared by The Samuelson Law, Technology & Public Policy Clinic (Unpublished & Confidential June 2006).
12. Andrew Smith, Dov Greenbaum, Shawn Douglas, H. Morrow Long, & Mark Gerstein, Computer and Network Security in Academia: an Assessment and Some Proposed Solutions, 6 GENOME BIOLOGY 119 (2005).
13. Dov Greenbaum, Shawn Douglas, Andrew Smith, Joanna Lim, Michael Fischer, Martin Schultz, & Mark Gerstein, The Challenge of Computer Security in Academia: A Potential Roadblock to Distributed Annotation of the Human Genome, 22 NATURE BIOTECHNOLOGY 771 (2004).
14. Dov Greenbaum, The Database Debate:  In Support of An Inequitable Solution, 13 ALB. L.J. SCI. & TECH. 431 (2003).
15. Dov Greenbaum, Are We Legislating Away Our Scientific Future?  The Database Debate, 22 Duke L. & Tech. Rev. (2003).
16. Dov Greenbaum, Know the Court’s Limits in Zealous Advocacy,  MCDERMOTT WILL & EMERY IP UPDATE (April 2009).
17. David Larson & Dov Greenbaum, The Convergence of Intellectual Property and Renewable Energy, MCDERMOTT WILL & EMERY INTERNATIONAL NEWS (2009).
18. Sheila Walcoff  & Dov Greenbaum,  Whose Gene is it Anyway? Patenting Personalized Medicine,  MCDERMOTT WILL & EMERY INTERNATIONAL NEWS (2009).
19. Dov Greenbaum & Paul Radensky, Personalized Medicine and the Changing Intellectual Property Landscape: Updating the Freedom To Operate Analysis,  AHLA Life Sciences Newsletter (2009).
20. Dov Greenbaum,  Single Antibody Disclosed in Specification Not Sufficient to Describe Densely Populated Genus,   MCDERMOTT WILL & EMERY IP UPDATE (November  2008).
21. Dov Greenbaum, Legal Concerns in Emerging Science: Synthetic Biology and Intellectual Property, Intellectual Property Law: Interdisciplinary Analysis (Miriam Bitton & Lior Zemer eds.) (Forthcoming 2012).
22. Dov Greenbaum, National Technology Transfer Mechanisms: A Comparison in THE ELGAR HANDBOOK ON LAW, INNOVATION AND GROWTH  (Robert Litan ed.) (Forthcoming 2011).
23. Dov Greenbaum & Mark Gerstein, Semantic Web Standards: Legal and Social Issues and Implications,  in SEMANTIC WEB: REVOLUTIONIZING KNOWLEDGE DISCOVERY IN THE LIFE SCIENCES (Christopher J. O. Baker & Kei-Hoi Cheung, eds.) (2006).
24. Ronald Jansen, Haiyuan Yu, Dov Greenbaum, Yuval Kluger, Nevan Krogan, Sambath Chung, Andrew Emili, Michael Snyder, Jack Greenblatt, & Mark Gerstein, A Bayesian Networks Approach For Predicting Protein-Protein Interactions From Genomic Data, 302 SCIENCE 449 (2003).
25. Dov Greenbaum, Christopher Colangelo, Kenneth Williams, & Mark Gerstein, Comparing Protein Abundance and mRNA Expression Levels on a Genomic Scale, 4 GENOME BIOLOGY 117 (2003).
26. Dov Greenbaum, Ronald Jansen, & Mark Gerstein, Analysis of mRNA Expression and Protein Abundance Data: An Approach for the Comparison of the Enrichment of Features in the Cellular Population of Proteins and Transcripts, 18 BIOINFORMATICS 585 (2002).
27. Aled Edwards, Bart Kus, Ronald Jansen, Dov Greenbaum, Jack Greenblatt, & Mark Gerstein, Bridging Structural Biology and Genomics:  Assessing Protein Interaction Data with Known Complexes, 18 TRENDS IN GENETICS 529 (2002).
28. Ronald Jansen, Dov Greenbaum*, & Mark Gerstein, Relating Whole-Genome Expression Data with Protein-Protein Interactions, 12 GENOME RESEARCH 37 (2002) (*joint first authorship).
29. Dov Greenbaum, Nicholas Luscombe, Ronald Jansen, Jiang Qian, & Mark Gerstein, Interrelating Different Types of Genomic Data, from Proteome to Secretome: ‘Oming In On Function, 11 GENOME RESEARCH 1463 (2001).
30. Nicholas Luscombe, Dov Greenbaum, & Mark Gerstein, What Is Bioinformatics? A Proposed Definition and Overview of the Field, 40 METHODS OF INFORMATION IN MEDICINE 346 (2001).

 

Practice areas

Industries

Find professionals by